Website
http://dataportal.arc.gov.au/NCGP/API/grants/LP210301109
Funding Status
Active
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Funded Activity Summary
A novel drug class for the effective treatment of Giardia infections. Companion animals play a pivotal role in the lifestyle of the average Australian family. The 9 million cats and dogs, residing in >65% of our households, have provided significant health and well-being benefits to owners, especially during COVID. Ensuring pet health is a primary obligation of pet ownership. Giardia infections (Giardia duodenalis, with 94% of infections in dogs identified as Assemblage A) is the most prevalent enteric parasite identified globally in dogs. Infection rates can be as high as 75% in puppies. Current treatments are failing due to poor efficacy, resistance and poor adherence to treatment schedules. We have identified a novel, extremely rapid acting series of compounds capable of single shot eradication of Giardia.Funded Activity Details
Start Date: 12-2023
End Date: 12-2026
Funding Scheme: Linkage Projects
Funding Amount: $282,339.00
Funder: Australian Research Council
Research Topics
ANZSRC Field of Research (FoR)
Veterinary Parasitology | Medicinal and Biomolecular Chemistry | Biologically Active Molecules | Veterinary Pharmacology
ANZSRC Socio-Economic Objective (SEO)
Expanding Knowledge in the Chemical Sciences | Expanding Knowledge in the Agricultural and Veterinary Sciences | Veterinary Pharmaceutical Treatments (e.g. Antibiotics) |
